Natalizumab



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Multiple Sclerosis 90.4%
Drug Use For Unknown Indication 2.6%
Pain 1.2%
Migraine Prophylaxis 0.7%
Depression 0.6%
Osteoporosis 0.5%
Affective Disorder 0.4%
Anxiety 0.4%
Contraception 0.4%
Routine Health Maintenance 0.4%
Constipation 0.3%
Vaginitis Bacterial 0.3%
Epilepsy 0.3%
Neurogenic Bladder 0.2%
Tremor 0.2%
Back Pain 0.2%
Crohn's Disease 0.2%
Hypertension 0.2%
Muscle Spasticity 0.2%
Relapsing-remitting Multiple Sclerosis 0.2%
Urinary Tract Infection 16.7%
Progressive Multifocal Leukoencephalopathy 13.9%
Vomiting 8.7%
Multiple Sclerosis 7.0%
Thrombosis 6.1%
White Blood Cell Count Increased 5.9%
Convulsion 5.2%
White Blood Cell Count Decreased 3.5%
Urosepsis 3.3%
Urticaria 3.3%
Pain 3.1%
Syncope 3.1%
Breast Cancer Female 2.8%
Myocardial Infarction 2.8%
Pyrexia 2.6%
Weight Decreased 2.6%
Pain In Extremity 2.4%
Upper Respiratory Tract Infection 2.4%
Malignant Melanoma 2.2%
Pneumonia 2.2%
Secondary
Multiple Sclerosis 80.0%
Product Used For Unknown Indication 8.3%
Crohn's Disease 4.9%
Drug Use For Unknown Indication 2.0%
Relapsing-remitting Multiple Sclerosis 1.5%
Back Pain 0.8%
Hypertension 0.8%
Type 2 Diabetes Mellitus 0.5%
Blood Oestrogen 0.2%
Fatigue 0.2%
Gait Disturbance 0.2%
Hypersomnia 0.2%
Pain 0.2%
Sepsis 0.2%
Infusion Related Reaction 8.8%
Urticaria 8.8%
Vomiting 7.7%
Completed Suicide 6.6%
Muscle Spasticity 6.6%
Urinary Tract Infection 6.6%
Malignant Melanoma 5.5%
Salivary Gland Cancer 5.5%
Drug Ineffective 4.4%
Pain In Extremity 4.4%
Patella Fracture 4.4%
Syncope 4.4%
Keratitis 3.3%
Large Intestine Perforation 3.3%
Pain 3.3%
Pancreatitis 3.3%
Progressive Multifocal Leukoencephalopathy 3.3%
Rash 3.3%
Skin Cancer 3.3%
Skin Reaction 3.3%
Concomitant
Product Used For Unknown Indication 22.0%
Drug Use For Unknown Indication 21.0%
Crohn's Disease 12.0%
Headache 8.5%
Multiple Sclerosis 8.0%
Pain 5.5%
Hypertension 4.5%
Smoking Cessation Therapy 4.5%
Relapsing-remitting Multiple Sclerosis 3.0%
Drug Ineffective 2.0%
Prophylaxis 2.0%
Neuropathy Peripheral 1.5%
Fatigue 1.0%
Migraine 1.0%
Osteoporosis 1.0%
Anaemia 0.5%
Depression 0.5%
Gait Disturbance 0.5%
Joint Ankylosis 0.5%
Muscle Spasms 0.5%
Heart Rate Decreased 17.2%
Off Label Use 6.9%
Pain 6.9%
Prinzmetal Angina 6.9%
Respiratory Disorder 6.9%
Tremor 6.9%
Aggression 3.4%
Back Pain 3.4%
Benign Neoplasm Of Thyroid Gland 3.4%
Blister 3.4%
Blood Immunoglobulin G Decreased 3.4%
Bone Pain 3.4%
Cardio-respiratory Arrest 3.4%
Completed Suicide 3.4%
Convulsion 3.4%
Drug Ineffective 3.4%
Hypersensitivity 3.4%
Hypertension 3.4%
Incisional Hernia 3.4%
Injection Site Haemorrhage 3.4%